Home > Newsroom > News Releases

Depression drug may relieve pain from breast cancer treatment, study finds

Drugs should be developed to target gene fusions in prostate cancer, research shows

--added 12/13/10

ANN ARBOR, MI -- A drug commonly used to treat depression and anxiety disorder was effective at reducing joint and muscle pain associated with a breast cancer treatment, according to a study from the University of Michigan Comprehensive Cancer Center.

The women in the study were taking aromatase inhibitors, a type of drug designed to block the production of estrogen, which fuels some breast cancers. About half of women taking these drugs experience aches and pains in their joints and muscles that cannot be adequately relieved by over-the-counter painkillers. Up to 20 percent of these women will stop taking an aromatase inhibitor because of this pain.

“Since women typically take these drugs for five years, it is important that the side effects not interfere too much with their quality of life, or they will be less likely to continue taking the medicine, which may lead to a greater chance of their breast cancer returning,” says study author N. Lynn Henry, M.D., Ph.D., assistant professor of internal medicine at the U-M Medical School.

Henry will present the initial results of the study Dec. 11 at the 33rd Annual San Antonio Breast Cancer Symposium.

The study looked at the drug duloxetine, or Cymbalta, which is used to treat depression and generalized anxiety disorder. It’s also been shown to work in multiple other chronic pain conditions, such as fibromyalgia and, more recently, osteoarthritis. It is believed to decrease pain through its actions in the central nervous system.

Of 29 patients evaluated, nearly three-quarters reported that their pain had decreased by at least 30%. On average, after eight weeks of treatment, pain scores declined 61%. Only one in five patients stopped taking duloxetine because of side effects.

“Duloxetine appears to be effective at reducing the muscle and joint pain many women experience from aromatase inhibitors, with only mild additional side effects,” Henry says.

The researchers are planning a randomized, controlled trial comparing duloxetine to placebo. Henry is also doing research looking at the effect of aromatase inhibitors on pain perception to better understand why women develop pain.

Breast cancer statistics: 209,060 Americans will be diagnosed with breast cancer this year and 40,230 will die from the disease, according to the American Cancer Society

Additional U-M authors: Mousumi Banerjee, Ph.D., Dorothy Blossom, Max Wicha, M.D., Catherine Van Poznak, M.D., Jeffrey Smerage, M.D., Ph.D., Anne Schott, M.D., Jennifer Griggs, M.D., M.P.H., and Daniel Hayes, M.D.

Funding: Supported by an Investigator Initiated Grant from Lilly Pharmaceuticals

Disclosure: None

Reference: 33rd Annual San Antonio Breast Cancer Symposium, Dec. 8-12, 2010, San Antonio, Texas

Resources

Cancer AnswerLine™, 800-865-1125

Breast cancer information

Cancer Clinical Trials on UMClinicalStudies.org.

 

Written by: Nicole Fawcett

Return to top


Small Text SizeMedium Text SizeLarge Text Size
Adjust text size

Speak with a Cancer nurse: 1-800-865-1125
make a donation
How You Can Help

Volunteer for a health study like this! Browse Cancer Clinical Trials on UMClinicalStudies.org.